The CustomGlycan Platform provides the unique opportunity to engineer glycans with high homogeneity and in a site-specific manner, thereby enabling novel applications such as activating glycan-mediated biological pathways. 

Leveraging Sialic acid-mediated therapy by engaging immune regulatory Siglecs 

  • CGP-201: anti-inflammatory clinical candidate anti-TNFα. Using tolerogenic α 2-6 Sialic acids that engage inhibitory Siglec checkpoint receptors.
  • CGP-301: Central nervous system, targeted therapeutic mAb

Exploiting natural protein degradation pathways of different cells and tissues enabled by engaging glycan specific scavenger receptors  

  • CGP-221: Glycan-mediated protein degradation 

Glycan-Targeted immunotherapy

  • CGP-401: anti-oncoglycan monoclonal antibody

Enhanced effector functions of therapeutic monoclonal antibodies enabled with a fully afucosylated N-glycan in the Fc domain

  • CGP-201: anti-inflammatory clinical candidate anti-TNFα
  • CGP-401: anti-oncoglycan monoclonal antibody 


Sialic Acid-Mediated Therapy

Large Market

  • Inflammatory Bowel disease (IBD) market size is estimated to be at least 8 Bn$ with TNFα inhibitors having the largest market share
  • A best-in-class drug candidate such as CGP-201 has the potential to secure a 2-3 Bn$ market share

High Unmet Medical Need

  • Despite TNFα inhibitors being the preferred and best first-line treatment, they suffer from significant primary and secondary treatment failure: more than 40% of patients lose response after 1 year
  • Treatment with TNFα inhibitors is complemented with corticosteroids and immunosuppressants to manage inflammation and ADA induction

Innovative Approach

  • CGP-201 combines novel glycan-mediated functions with the well-known and validated TNFαneutralization effect 
  • Full enabling of Fc effector functions (enhanced ADCC and recruitment of wound healing macrophages) and reduction in anti-drug antibodies (ADA) can significantly enhance efficacy and result in a continuous and higher response
  • Higher efficacy in terms of clinical remission of CGP-201 is expected to result in a monotherapy (no need to use corticosteroid), a lower dose (due to higher efficacy), lower dosing frequency (due to the positive effect of sialylated molecules on serum half-life) and reduced loss of response (due to lower ADA potential)

CGP-201 Development Plan

  • Fast 12 weeks clinical POC possible due to significant adalimumab-related ADA induction in healthy subjects
  • Followed by an active controlled trial in ulcerative colitis patients to demonstrate CGP-201 efficacy

High Unmet Medical Need

  • Tremendous unmet medical need in the treatment of complex neurological diseases
  • Addressing biological drugs to the CNS across the blood brain barrier is a technological challenge

Innovative Approach

  • Antibody blood-brain barrier efflux is modulated by glycan modification (Finke, 2017)
  • The CustomGlycan Platform is currently used to exploit glycoengineering of different therapeutics to reduce brain efflux
  • Collaboration with an established biotech company focused in CNS field
  • Early preclinical PoC achieved!

Glycan-Mediated Protein Degradation

High Unmet Medical Need

  • Addressing unmet medical need in inflammatory, autoimmune and cancer disease
  • Targeting diseases that are difficult to treat

Innovative Approach

  • Exploiting natural protein degradation pathways 
  • Novel approach leveraging a specific glycan structure dependent endocytosis/lysosomal degradation pathway of different cells and tissues 
  • Big potential for novel therapeutics development

Glycan-Targeted Immunotherapy

High Unmet Medical Need

  • High need for new therapeutic approaches in several cancer indications (NSCLC, colorectal, ovarian etc.)
  • Side effects of current treatments are high; need for truly cancer-specific therapeutic targets

Innovative Approach

  • Aberrant glycan antigens in cancer known to be prime targets for immuno-oncology: highly tumor specific 
  • Low immunogenicity of oncoglycans has hindered mAb development to date
  • Breaking the immune tolerance through glycoengineered oncoglycan antigen exposed on a highly immunogenic lipid particle > highly specific mAb generation
  • Production of glyco-optimized mAbs with superior efficacy
  • Supported by CHF 0.8M Switzerland Innosuisse grant